VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)

被引：0
|
作者：
Loupakis, F. [1 ]
Ruzzo, A. [2 ]
Salvatore, L. [1 ]
Canestrari, E. [2 ]
Cremolini, C. [1 ]
Masi, G. [1 ]
Schirripa, M. [1 ]
Spoto, C. [3 ]
Galluccio, N. [2 ]
Vincenzi, B. [3 ]
Santini, D. [3 ]
Bencardino, K. [4 ]
Ricci, V [4 ]
Catalano, V [5 ]
Manzoni, M. [6 ]
Danova, M. [6 ]
Tonini, G. [3 ]
Magnani, M. [2 ]
Falcone, A. [1 ,7 ]
Graziano, F. [5 ]
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med Univ 2, Pisa, Italy
[2] Univ Carlo Bo, Dipartimento Sci Biomol, Urbino, Italy
[3] Univ Campus Biomed, UO Oncol Med, Rome, Italy
[4] Ist Sci Univ San Raffaele, UO Oncol Med, Milan, Italy
[5] Osped Pesaro, UO Oncol Med, Pesaro, Italy
[6] Policlin San Matteo, Fdn IRCCS, UO Oncol Med, Pavia, Italy
[7] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, I-56100 Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [2] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [3] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    Annamaria Ruzzo
    Lisa Salvatore
    Chiara Cremolini
    Gianluca Masi
    Paolo Frumento
    Marta Schirripa
    Vincenzo Catalano
    Nadia Galluccio
    Emanuele Canestrari
    Bruno Vincenzi
    Daniele Santini
    Katia Bencardino
    Vincenzo Ricci
    Mariangela Manzoni
    Marco Danova
    Giuseppe Tonini
    Mauro Magnani
    Alfredo Falcone
    Francesco Graziano
    [J]. BMC Cancer, 11
  • [4] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Loupakis, Fotios
    Ruzzo, Annamaria
    Salvatore, Lisa
    Cremolini, Chiara
    Masi, Gianluca
    Frumento, Paolo
    Schirripa, Marta
    Catalano, Vincenzo
    Galluccio, Nadia
    Canestrari, Emanuele
    Vincenzi, Bruno
    Santini, Daniele
    Bencardino, Katia
    Ricci, Vincenzo
    Manzoni, Mariangela
    Danova, Marco
    Tonini, Giuseppe
    Magnani, Mauro
    Falcone, Alfredo
    Graziano, Francesco
    [J]. BMC CANCER, 2011, 11
  • [5] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Bernard, M. A.
    Grelaud, A.
    Smith, D.
    Ravaud, A.
    Moore, N.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S28 - S28
  • [8] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] PROSPECTIVE EVALUATION OF CANDIDATE SNPS OF VEGF/VEGFR PATHWAY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV)
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuky, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Maus, Martin
    Bocci, Guido
    Falcone, Alfredo
    Lenz, Heinz Joseph
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 105 - 106
  • [10] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
12345